Obesity Treatment Advances: Foundayo and Oral Wegovy Lead Oral GLP-1 Market, Retatrutide Shows Significant Weight Loss in Phase II

July 26, 2026

GoodRx Health USA

Overview

The obesity therapeutics market is rapidly evolving, with Foundayo (orforglipron) and oral Wegovy driving the oral GLP-1 segment. Foundayo, FDA-approved on April 1, 2026, offers the novel advantage of being taken anytime without food restrictions. Furthermore, investigational GLP-1/GIP/glucagon triple agonist retatrutide shows highly promising results, including substantial weight loss in Phase II trials. These new medications provide more diverse and effective treatment options for patients with obesity, accelerating market expansion.

In Depth

Key Findings

The landscape of obesity pharmacotherapy is undergoing a significant transformation with the emergence and advancement of several novel agents. Leading this charge are the oral GLP-1 receptor agonists, specifically Foundayo (orforglipron), which received FDA approval on April 1, 2026, and the oral formulation of Wegovy (semaglutide), approved in December 2025. Beyond these, investigational multi-agonist therapies like retatrutide are demonstrating highly promising results, including substantial weight loss in Phase II trials, signaling a new era for obesity management.

Technical / Clinical Details

Foundayo differentiates itself from oral semaglutide (oral Wegovy) by not requiring specific meal-related timing restrictions, offering greater flexibility for patients. In clinical trials, oral Wegovy achieved an average weight reduction of 14% over 64 weeks, while Foundayo demonstrated an average weight loss of 11.1% over 72 weeks, both representing significant efficacy compared to older weight-loss medications. Eli Lilly’s retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, has reported remarkably robust weight loss outcomes in its Phase II trials. Similarly, survodutide, a dual glucagon receptor/GLP-1 receptor agonist, has shown favorable results in Phase III studies, and berobenatide, a once-monthly injectable GLP-1, presented promising data from its Phase IIb trial.

Background & Context

Obesity is a major global health concern and a significant risk factor for numerous chronic conditions, including cardiovascular disease, type 2 diabetes, and certain cancers. Historical weight-loss medications have often been limited by side effects or modest efficacy. The advent of GLP-1 receptor agonists marked a substantial advance, and the introduction of oral formulations significantly improves patient convenience and adherence. The development of multi-agonist therapies, which target multiple hormonal pathways, holds the potential for even greater and more sustained weight loss, addressing a high unmet medical need in the obesity patient population.

Strategic Significance & Outlook

The introduction of these novel obesity drugs is intensifying market competition and is set to elevate the standard of care for obesity. The widespread availability of oral GLP-1 agonists, in particular, will improve access to treatment for a larger patient population. If innovative agents like the triple agonists continue to advance through clinical development and receive approval, therapeutic efficacy for obesity is expected to further improve, contributing significantly to reducing the risks of associated comorbidities. In the future, personalized treatment strategies combining these pharmacotherapies with lifestyle interventions are likely to be established, enhancing comprehensive management for obesity and its related conditions.

Source: https://www.weightwatchers.com/us/blog/weight-loss/new-weight-loss-drugs

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.